BioNxt Solutions Inc. (CVE:BNXT)

PRESS RELEASE

published on 12/17/2025 at 09:05, 10 months 23 days ago

Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
BioNxt Solutions Inc. announces breakthrough in drug delivery for dysphagia, securing first national-level patent for thin-film platform, targeting autoimmune markets with bioequivalent cladribine treatment

BioNxt Solutions Inc. Drug Delivery Dysphagia Thin-film Platform Autoimmune Markets
BRIEF

published on 12/09/2025 at 09:10, 11 months ago

BioNxt développe une cladribine « fondante » pour les patients atteints de SEP.

Sclérose En Plaques Cladribine Solutions BioNxt Administration De Médicaments Fond Dans La Bouche
BRIEF

published on 12/09/2025 at 09:10, 11 months ago

BioNxt Develops "Melt in Your Mouth" Cladribine for MS Patients

Multiple Sclerosis Cladribine BioNxt Solutions Melt In Your Mouth Drug-delivery
PRESS RELEASE

published on 12/09/2025 at 09:05, 11 months ago

BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
BioNxt Solutions Inc. is developing a sublingual cladribine ODF to enhance MS treatment access. The innovative technology aims to improve swallowing difficulties and increase therapy adherence

BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Cladribine ODF Melt In Your Mouth
BRIEF

published on 12/01/2025 at 09:10, 11 months 8 days ago

BioNxt Solutions to Acquire IP for Sublingual Chemotherapy Drug

Intellectual Property Chemotherapy BioNxt Solutions Sublingual Drug Immunosuppressant Market
BRIEF

published on 12/01/2025 at 09:10, 11 months 8 days ago

BioNxt Solutions va acquérir la propriété intellectuelle d'un médicament de chimiothérapie sublinguale

Propriété Intellectuelle Chimiothérapie Solutions BioNxt Médicament Sublingual Marché Des Immunosuppresseurs
PRESS RELEASE

published on 12/01/2025 at 09:05, 11 months 8 days ago

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio

Oncology BioNxt Solutions European Chemotherapy Company Sublingual Drug Formulation Immunosuppressant
BRIEF

published on 11/20/2025 at 09:10, 11 months 19 days ago

BioNxt Receives Eurasian Patent for Sublingual Cladribine Platform

Global Market Autoimmune Diseases Patent Grant BioNxt Solutions Sublingual Cladribine
BRIEF

published on 11/20/2025 at 09:10, 11 months 19 days ago

BioNxt obtient un brevet eurasien pour sa plateforme de cladribine sublinguale

Marché Mondial Maladies Auto-immunes Solutions BioNxt Cladribine Sublinguale Brevet Accordé
PRESS RELEASE

published on 11/20/2025 at 09:05, 11 months 19 days ago

BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
BioNxt Solutions Inc. receives Eurasian Patent No. 051510 for sublingual anticancer drug delivery system, a key milestone in global IP strategy. Expansion to EU and US markets in progress

BioNxt Solutions Inc. Sublingual Delivery Eurasian Patent Pharmaceutical Markets Global IP Strategy

Published on 11/10/2026 at 02:45, 1 hour 31 minutes ago

Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 5 hours 6 minutes ago

Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 5 hours 16 minutes ago

LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 5 hours 44 minutes ago

Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 6 hours 1 minute ago

Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley

View all ACCESSWIRE

Published on 11/10/2026 at 01:20, 2 hours 55 minutes ago

US defence customer steps up orders and first graphene oxide orders secured
Published on 11/09/2026 at 23:35, 4 hours 40 minutes ago

KPS to Acquire MM Packaging from MM Group
Published on 11/09/2026 at 22:54, 5 hours 22 minutes ago

EQS-Adhoc: Northern Data Group reports Q3 2026 and raises its FY 2026 revenue outlook communicated on 17 June 2026
Published on 11/09/2026 at 22:10, 6 hours 5 minutes ago

Quantinuum to Participate in the Cantor Convergence 4th Annual Crypto, FinTech, AI & Energy Infrastructure Conference
Published on 11/09/2026 at 22:05, 6 hours 11 minutes ago

Mayr-Melnhof Karton AG: MM Group to sell majority stake in its Packaging business to KPS Capital Partners and plans a special distribution to shareholders

View all EQS

Published on 11/09/2026 at 18:30, 9 hours 46 minutes ago

Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 9 hours 46 minutes ago

Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
Published on 11/09/2026 at 17:45, 10 hours 31 minutes ago

Weekly share buyback
Published on 11/09/2026 at 17:45, 10 hours 31 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 11/09/2026 at 17:45, 10 hours 31 minutes ago

Déclaration des droits de vote à fin octobre 2026

View all LES ECHOS COMFI WIRE

News